The Russian Ministry of Health has granted a registration certificate for Semavik (semaglutide), which is the first generic alternative to Ozempic. Originally developed for treating type 2 diabetes, this medication is now also effectively combating excessive weight gain.
The Russian Ministry of Health granted permission to Geropharm, a Russian company, in June 2023, to commence the inaugural phase of clinical trials for the drug. The first phase of the injectable drug, codenamed GP40221 (semaglutide), was reported to last until May 2024. “The end of clinical trials is officially scheduled for May 2024. But we expect that we will be able to complete them in a shorter period of time in accordance with all standards of good practice. Patients should gain access to an analogue as soon as possible, given that the foreign drug is already out of stock” said the CEO of the company back then.